Business
Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
CHAPEL HILL, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place virtually from April 7-10, 2025. Details of presentation: Format: Corporate Presentation Participants: Chris Giordano,
About this update from Tenax Therapeutics, Inc.
[{"type":"image","alt":"Tenax Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Tenax Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":86,"url":"https://media.zenfs.com/en/globenewswire.com/086764dfb6bc07a5373ff5909c69dd8a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0Yzp0.DOU_ACRbjGKAg31w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/086764dfb6bc07a5373ff5909c69dd8a","width":300,"height":86}},"lazy":false},{"type":"text","content":"CHAPEL HILL, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place virtually from April 7-10, 2025.","length":413,"tagName":"p"},{"type":"text","content":"Details of presentation:","length":24,"tagName":"p"},{"type":"text","content":"Format: Corporate Presentation","length":30,"tagName":"p"},{"type":"text","content":"Participants: Chris Giordano, President & Chief Executive Officer, Stuart Rich, M.D., Chief Medical Officer, Doug Randall, Chief Business Officer","length":149,"tagName":"p"},{"type":"text","content":"Date and Time: April 7, 2025, at 3:45 p.m. ET","length":45,"tagName":"p"},{"type":"text","content":"The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage.","length":120,"tagName":"p"},{"type":"text","content":"About Tenax Therapeutics","length":24,"tagName":"p"},{"type":"text","content":"Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit www.tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.","length":530,"tagName":"p"},{"type":"text","content":"Contact:","length":8,"tagName":"p"},{"type":"text","c...